TABLE 7.

Adverse events associated with Golden-Antrodia Camphorata consumption (Safety Set).

System organ class	Test (N = 53)		Placebo (N = 51)		Total (N = 104)
Preferred term	N (%)	Case number	N (%)	Case number	N (%)	Case number
Gastrointestinal disorders	2 (3.77)	4	0 (0.00)	0	2 (1.92)	4
Abdominal pain	1 (1.89)	2	0 (0.00)	0	1 (0.96)	2
Diarrhea	2 (3.77)	2	0 (0.00)	0	2 (1.92)	2
General disorders and administration site conditions	1 (1.89)	1	0 (0.00)	0	1 (0.96)	1
Fatigue	1 (1.89)	1	0 (0.00)	0	1 (0.96)	1
Infections and infestations	1 (1.89)	1	1 (1.96)	1	2 (1.92)	2
Bronchitis	1 (1.89)	1	0 (0.00)	0	1 (0.96)	1
Nasopharyngitis	0 (0.00)	0	1 (1.96)	1	1 (0.96)	1
Injury, poisoning and procedural complications	1 (1.89)	1	0 (0.00)	0	1 (0.96)	1
Lip injury	1 (1.89)	1	0 (0.00)	0	1 (0.96)	1
Musculoskeletal and connective tissue disorders	0 (0.00)	0	1 (1.96)	1	1 (0.96)	1
Back pain	0 (0.00)	0	1 (1.96)	1	1 (0.96)	1
Nervous system disorders	2 (3.77)	2	0 (0.00)	0	2 (1.92)	2
Headache	2 (3.77)	2	0 (0.00)	0	2 (1.92)	2
Respiratory, thoracic and mediastinal disorders	1 (1.89)	1	0 (0.00)	0	1 (0.96)	1
Rhinitis allergic	1 (1.89)	1	0 (0.00)	0	1 (0.96)	1
Skin and subcutaneous tissue disorders	2 (3.77)	2	1 (1.96)	1	3 (2.88)	3
Eczema	1 (1.89)	1	1 (1.96)	1.96	2	1.92
Urticaria	1 (1.89)	1	0 (0.00)	0	1 (0.96)	1
Totoal a	9 (16.98)	12	3 (5.88)	3	12 (11.54)	15

^aAccumulated total (number of cases).